<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
                      "http://www.w3.org/TR/html4/strict.dtd">
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=us-ascii">
<meta name="generator" content="hypermail 2.1.5, see http://www.hypermail.org/">
<title>Extropians: Re: Performance enhancement with selegiline</title>
<meta name="Author" content="Alex Ramonsky (alex@ramonsky.com)">
<meta name="Subject" content="Re: Performance enhancement with selegiline">
<meta name="Date" content="2003-02-08">
<style type="text/css">
body {color: black; background: #ffffff}
h1.center {text-align: center}
div.center {text-align: center}
</style>
</head>
<body>
<h1>Re: Performance enhancement with selegiline</h1>
<!-- received="Sat Feb  8 04:23:27 2003" -->
<!-- isoreceived="20030208112327" -->
<!-- sent="Sat, 08 Feb 2003 11:30:05 +0000" -->
<!-- isosent="20030208113005" -->
<!-- name="Alex Ramonsky" -->
<!-- email="alex@ramonsky.com" -->
<!-- subject="Re: Performance enhancement with selegiline" -->
<!-- id="3E44EA3C.7070306@ramonsky.com" -->
<!-- charset="us-ascii" -->
<!-- inreplyto="BMEDJIBJGLNDOOANGIDLGEKOCJAA.rms2g@virginia.edu" -->
<!-- expires="-1" -->
<p>
<strong>From:</strong> Alex Ramonsky (<a href="mailto:alex@ramonsky.com?Subject=Re:%20Performance%20enhancement%20with%20selegiline"><em>alex@ramonsky.com</em></a>)<br>
<strong>Date:</strong> Sat Feb 08 2003 - 04:30:05 MST
</p>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2311.html">Anders Sandberg: "Re: PD"</a>
<ul>
<li><strong>Previous message:</strong> <a href="2309.html">gts: "Re: Performance enhancement with selegiline"</a>
<li><strong>In reply to:</strong> <a href="2271.html">Rafal Smigrodzki: "RE: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2318.html">gts: "Re: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2318.html">gts: "Re: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2350.html">Rafal Smigrodzki: "Re: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2310">[ date ]</a>
<a href="index.html#2310">[ thread ]</a>
<a href="subject.html#2310">[ subject ]</a>
<a href="author.html#2310">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<hr>
<!-- body="start" -->
<p>
Gentlemen;
<br>
I do not know if this is relevant to your discussion, and please forgive 
<br>
me for butting in, but...
<br>
<p>...'Geddy' has been taking Selegiline (R-(-)-Deprenyl hydrochloride)  @ 
<br>
20mg daily  since 21st December 2002. Geddy is a 44-year-old male human 
<br>
in average health who does not suffer from any neurological disorder, 
<br>
and is basically taking selegiline to see what happens.
<br>
We are monitoring him. He intends to stay on the drug indefinitely 
<br>
unless there are deleterious effects.
<br>
For obvious reasons Geddy wishes to remain low-profile! We're happy to 
<br>
discuss this trial and any clinical results if contacted WITH PGP at 
<br>
&nbsp;<a href="mailto:alex@ramonsky.com?Subject=Re:%20Performance%20enhancement%20with%20selegiline">alex@ramonsky.com</a>
<br>
He is however happy for the world to know the following:
<br>
He has noticed several changes since beginning the trial. The first 
<br>
change was an increase in confidence, he felt calmer and less shy and 
<br>
was able to communicate more easily. He felt more confident and 
<br>
assertive in business environments. Then he noticed that an annoying 
<br>
nervous habit of wiggling his toes had stopped. He feels he can control 
<br>
his emotions more sensibly and think more rationally under stress.
<br>
His dreams have become more vivid, and he feels his fantasy life and 
<br>
imagination have improved. He explains an odd sensation of 'thinking too 
<br>
fast to be able to verbalise it', which is the only downer so far. On 
<br>
the whole he seems a great deal happier as an individual.
<br>
We may have to wait some time to see if he lives longer, of course. But 
<br>
other data are coming in, all along the way. As far as I know, this is 
<br>
the first trial of a healthy human?
<br>
: )
<br>
AR
<br>
<p>Rafal Smigrodzki wrote:
<br>
<p><em>&gt;gts wrote:
</em><br>
<em>&gt;
</em><br>
<em>&gt;  
</em><br>
<em>&gt;
</em><br>
<em>&gt;&gt;Many, many dozens of published studies state, suggest, or offer
</em><br>
<em>&gt;&gt;evidence of the neuroprotective value of selegiline in PD.
</em><br>
<em>&gt;&gt;    
</em><br>
<em>&gt;&gt;
</em><br>
<em>&gt;
</em><br>
<em>&gt;### Show me any class A studies to this effect.
</em><br>
<em>&gt;
</em><br>
<em>&gt;Listing dozens of animal studies is perfectly irrelevant - in clinical
</em><br>
<em>&gt;medicine animal studies are not even class C evidence, they are not evidence
</em><br>
<em>&gt;at all.
</em><br>
<em>&gt;
</em><br>
<em>&gt;&quot;Neuroprotection in PD&quot; means that the rate of neuron loss is reduced
</em><br>
<em>&gt;compared to a control group. There must be a clinical effect, or else the
</em><br>
<em>&gt;neuroprotection (if detected post mortem) is useless.
</em><br>
<em>&gt;
</em><br>
<em>&gt;There must be either, maintenance of UPDRS improvement after washout of the
</em><br>
<em>&gt;drug, or delay to untreatable disability, or delay of death. Neither
</em><br>
<em>&gt;occurred in DATATOP.
</em><br>
<em>&gt;
</em><br>
<em>&gt;The class A study, DATATOP, shows no evidence of clinically significant
</em><br>
<em>&gt;neuroprotection. Period. End of discussion.
</em><br>
<em>&gt;
</em><br>
<em>&gt;------------------
</em><br>
<em>&gt;  
</em><br>
<em>&gt;
</em><br>
<em>&gt;&gt;&gt;&gt;As background: there was once a hypothesis that levodopa
</em><br>
<em>&gt;&gt;&gt;&gt;accelerates the attrition of dopaminergic neurons, and that
</em><br>
<em>&gt;&gt;&gt;&gt;levodopa-sparing therapy would delay the onset of dyskinesias which
</em><br>
<em>&gt;&gt;&gt;&gt;usually develop after about 5-7 years on levodopa, and perhaps
</em><br>
<em>&gt;&gt;&gt;&gt;prolong survival. A nice hypothesis, but not true -substituting
</em><br>
<em>&gt;&gt;&gt;&gt;dopa-agonists or selegiline for levodopa in initial treatment does
</em><br>
<em>&gt;&gt;&gt;&gt;not delay the onset of dyskinesia. ...
</em><br>
<em>&gt;&gt;&gt;&gt;        
</em><br>
<em>&gt;&gt;&gt;&gt;
</em><br>
<em>&gt;&gt;I think are mistaken here to include selegiline in the same class of
</em><br>
<em>&gt;&gt;drugs as levodopa. Levodopa is merely a simple dopamine agonist --
</em><br>
<em>&gt;&gt;actually it's not even that -- it's merely an ordinary amino acid and
</em><br>
<em>&gt;&gt;a precursor to dopamine. Selegiline's actions are far more complex
</em><br>
<em>&gt;&gt;and less well understood.
</em><br>
<em>&gt;&gt;    
</em><br>
<em>&gt;&gt;
</em><br>
<em>&gt;
</em><br>
<em>&gt;### I think you are mistaken to say I included selegiline in the same class
</em><br>
<em>&gt;of drugs as levodopa.
</em><br>
<em>&gt;
</em><br>
<em>&gt;------------------------
</em><br>
<em>&gt;
</em><br>
<em>&gt;
</em><br>
<em>&gt;  
</em><br>
<em>&gt;
</em><br>
<em>&gt;&gt;If you were really on top of this subject, Rafal, then I believe you
</em><br>
<em>&gt;&gt;and I would not be arguing whether selegiline is neuroprotective.
</em><br>
<em>&gt;&gt;    
</em><br>
<em>&gt;&gt;
</em><br>
<em>&gt;
</em><br>
<em>&gt;### OK, I am just too incompetent to discuss PD with you.
</em><br>
<em>&gt;
</em><br>
<em>&gt;All my years of training as a neurologist, my movement disorders fellowship,
</em><br>
<em>&gt;and you simply crush me with the abstracts of a few little rat studies.
</em><br>
<em>&gt;
</em><br>
<em>&gt;On the other hand, if you were a neurologist and a scientist you would not
</em><br>
<em>&gt;waste anybody's time with fuzzy tissue-culture experiments and try to treat
</em><br>
<em>&gt;them as adequate arguments against double-blind placebo controlled studies.
</em><br>
<em>&gt;
</em><br>
<em>&gt;-----------------------
</em><br>
<em>&gt;
</em><br>
<em>&gt; Other studies show
</em><br>
<em>&gt;  
</em><br>
<em>&gt;
</em><br>
<em>&gt;&gt;that selegiline increases lifespan in &lt;snip&gt; human PD
</em><br>
<em>&gt;&gt;patients.
</em><br>
<em>&gt;&gt;
</em><br>
<em>&gt;&gt;    
</em><br>
<em>&gt;&gt;
</em><br>
<em>&gt;### Quote them and show they are more reliable and trustworthy than DATATOP.
</em><br>
<em>&gt;
</em><br>
<em>&gt;Rafal
</em><br>
<em>&gt;
</em><br>
<em>&gt;
</em><br>
<em>&gt;
</em><br>
<em>&gt;  
</em><br>
<em>&gt;
</em><br>
<!-- body="end" -->
<hr>
<ul>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2311.html">Anders Sandberg: "Re: PD"</a>
<li><strong>Previous message:</strong> <a href="2309.html">gts: "Re: Performance enhancement with selegiline"</a>
<li><strong>In reply to:</strong> <a href="2271.html">Rafal Smigrodzki: "RE: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2318.html">gts: "Re: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2318.html">gts: "Re: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2350.html">Rafal Smigrodzki: "Re: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2310">[ date ]</a>
<a href="index.html#2310">[ thread ]</a>
<a href="subject.html#2310">[ subject ]</a>
<a href="author.html#2310">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<!-- trailer="footer" -->
<hr>
<p><small><em>
This archive was generated by <a href="http://www.hypermail.org/">hypermail 2.1.5</a> 
: Sat Feb 08 2003 - 04:25:40 MST
</em></small></p>
</body>
</html>
